On Feb. 15, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval of Tepmetko (tepotinib) for people living with metastatic non-small cell lung cancer (NSCLC) with a MET-Exon 14 mutation. Tepmetko (tepotinib) initially received accelerated approval in [...]
What happens when your cancer becomes resistant to your course of treatment and progresses? That’s the question we explored in the September episode of our Lung Cancer Living Room series. Dr. David Gandara, professor emeritus and co-director of UC [...]
Author: Andrew Ciupek, PhD, Associate Director, Clinical Research Targeted therapy research was front and center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Data was presented from several studies detailing new targeted therapies and better understanding [...]
On February 3rd, 2021, the Food and Drug Administration (FDA) approved Tepmetko (tepotinib) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in MET called exon 14 skipping. The FDA based their approval on the results of [...]
By Rashmi Acharya, MS; Andrew Ciupek, PhD; Jennifer C. King, PhD; Amy C. Moore, PhD; Daniel Saez, MS; Jacinta Wiens, PhD This past weekend was the ASCO Annual Meeting with presentations of some of the most important lung cancer [...]